Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2020, with a specific transaction notification dated October 12, 2020. The filing serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a specific disclosure of a share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £14.2540 |
| Volume | 3,700.601 shares |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing details an acquisition of 3,700.601 ordinary shares by Ms. E Walmsley, the Chief Executive Officer. This transaction resulted from the re-investment of dividends paid to shareholders on October 8, 2020, on shares held in the Company's Performance Share Plan. These shares are subject to a 2-year holding period. No other material changes to the company's financial position are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly a regulatory notification of a specific share transaction.
Key Facts for Investor Verification
- Executive Action: CEO Emma Walmsley acquired shares via dividend reinvestment.
- Transaction Date: October 12, 2020.
- Share Price: The acquisition occurred at a price of £14.2540 per share.
- Restrictions: The acquired shares are subject to a 2-year holding period under the Performance Share Plan.
- Scope: This filing does not contain quarterly or annual financial performance data.